CD274 and cancer: Despite important clinical benefits, cancer treatments with PD-1 / PD-L1 inhibitors are associated with a unique spectrum of treatment-related adverse events (AEs) that reflect a homeostatic imbalance in the regulation of the immune system, with multiple and not fully known pathogenesis mechanisms [16].